Automate Your Wheel Strategy on CELC
With Tiblio's Option Bot, you can configure your own wheel strategy including CELC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CELC
- Rev/Share 0.0028
- Book/Share 1.0163
- PB 49.5721
- Debt/Equity 2.2403
- CurrentRatio 4.5844
- ROIC -1.0198
- MktCap 2137386412.0
- FreeCF/Share -1.9407
- PFCF -25.223
- PE -14.7923
- Debt/Assets 0.5415
- DivYield 0
- ROE -1.5007
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CELC | Stifel | -- | Buy | -- | $30 | July 1, 2025 |
News
Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript
Published: August 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Celcuity Inc. (NASDAQ:CELC ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Brian F. Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Eason Lee - Leerink Partners LLC, Research Division Frances Dovell - TD Cowen, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Apoorva Chaloori - Unidentified Company Operator Good afternoon, ladies and gentlemen, and …
Read More
Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Celcuity's phase 3 VIKTORIA-1 trial showed gedatolisib significantly improved progression-free survival in PIK3CA wild-type HR+/HER2- advanced breast cancer patients. NDA submission for gedatolisib in 2nd-line PIK3CA wild-type HR+/HER2- ABC patients is planned for Q4 2025, with expansion to mutant and 1st-line cohorts underway as well. Strong market opportunity exists as HR+/HER2- breast cancer represents 70% of all breast cancers; Data from PIK3CA-mutant cohort expected by end of 2025.
Read More
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offering of $175,000,000 aggregate principal amount of its 2.750% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”), and its underwritten public offering of 1,836,842 of shares of its common stock (the “Common Stock”) at a public offering price of $38.00 per share and, in lieu of Common Stock to investors who so choose, pre-funded warrants to purchase up to 400,000 shares …
Read More
Biotech Stock Blasting Off After Late-Stage Trial Results
Published: July 28, 2025 by: Schaeffers Research
Sentiment: Positive
Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes will have Food & Drug Administration (FDA) approval by the end of the year.
Read More
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity's patent exclusivity in the U.S. into 2042.
Read More
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
Read More
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Read More
About Celcuity Inc. (CELC)
- IPO Date 2017-09-20
- Website https://www.celcuity.com
- Industry Biotechnology
- CEO Brian F. Sullivan
- Employees 87